Iovance Biotherapeutics shares rally on receiving FDA priority review for melanoma drugProactive Investors • 05/30/23
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced MelanomaGlobeNewsWire • 05/26/23
Iovance Biotherapeutics Reports First Quarter 2023 Financial Results and Corporate UpdatesGlobeNewsWire • 05/09/23
Iovance Biotherapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, May 9, 2023GlobeNewsWire • 05/02/23
Iovance Progresses Despite Challenges In Developing Potency Assays For LifileucelSeeking Alpha • 04/23/23
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)PRNewsWire • 04/19/23
Why Is Iovance Biotherapeutics (IOVA) Down 9.2% Since Last Earnings Report?Zacks Investment Research • 03/30/23
Iovance Biotherapeutics completes license application submission for advanced melanoma therapy; shares rallyMarket Watch • 03/24/23
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced MelanomaGlobeNewsWire • 03/24/23
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate UpdatesGlobeNewsWire • 02/28/23
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Tuesday, February 28, 2023GlobeNewsWire • 02/21/23